Pharmacoeconomic review report : Preservative-free latanoprost 50 [mu]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)

Pharmacoeconomic review report Preservative-free latanoprost 50 [mu]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)

Preservative-free latanoprost (Monoprost) is available as a sterile ophthalmic solution in a single-dose container (50 mcg/mL). Health Canada approved Monoprost for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OH) or open-angle glaucoma (OAG). The manufacturer is...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : CADTH 2018.
Colección:Common drug review clinical review report.
Materias:
Drugs > Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268506719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of Identified Limitations and Key Results
  • Conclusions
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's Pharmacoeconomic Submission
  • Manufacturer's Base Case
  • Summary of Manufacturer's Sensitivity Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Issues for Consideration
  • Patient Input
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Summary of Key Outcomes
  • Appendix 3. Additional Information
  • Appendix 4. Summary of Other Health Technology Assessment Reviews of Drug
  • Appendix 5. Reviewer Worksheets
  • References.

Ejemplares similares